VIPoma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
Line 15: | Line 15: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] |
Latest revision as of 00:39, 30 July 2020
VIPoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
VIPoma cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of VIPoma cost-effectiveness of therapy |
Risk calculators and risk factors for VIPoma cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
Cost-effectiveness of Therapy
References